CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune check ...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 20 other locations
study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial...
Phase 2
Pittsburgh, Pennsylvania, United States and 20 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
Pittsburgh, Pennsylvania, United States and 200 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Pittsburgh, Pennsylvania, United States and 202 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Pittsburgh, Pennsylvania, United States and 162 other locations
in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSigna...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 67 other locations
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict...
Phase 2
Pittsburgh, Pennsylvania, United States and 14 other locations
advanced solid tumors. Subjects with all histologic types of solid tumors are eligible for the escalation and dose-finding portion ...
Phase 1
Pittsburgh, Pennsylvania, United States and 10 other locations
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, wit...
Phase 3
Pittsburgh, Pennsylvania, United States and 230 other locations
objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator in participants pro ...
Phase 2
Pittsburgh, Pennsylvania, United States and 40 other locations
Clinical trials
Research sites
Resources
Legal